Cited by 15,011Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of LifeVoice and Speech Disorders

The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Kurtzke, John F.·1983·Neurology

DOI 10.1212/wnl.33.11.1444

Open this paper in CoChat — free account

Abstract

One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 . . . 9) now divided into two (1.0, 1.5, 2.0 . . . 9.5). The lower portion is obligatorily defined by Functional System grades. The FS are Pyramidal, Cerebellar, Brain Stem, Sensory, Bowel & Bladder, Visual, Cerebral, and Other; the Sensory and Bowel & Bladder Systems have been revised. Patterns of FS and relations of FS by type and grade to the DSS are demonstrated.

Integrity signals

Registry

Crossref · 10.1212/wnl.33.11.1444

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

On the evaluation of disability in multiple sclerosis
Kurtzke, J. F. (1961) · Neurology · doi:10.1212/wnl.11.8.686 · Cited by 330
Further notes on disability evaluation in multiple sclerosis, with scale modifications
Kurtzke, J. F. (1965) · Neurology · doi:10.1212/wnl.15.7.654 · Cited by 309
A New Scale for Evaluating Disability in Multiple Sclerosis
Kurtzke, J. F. (1955) · Neurology · doi:10.1212/wnl.5.8.580 · Cited by 305
Appreciating the consequences of disease: the international classification of impairments, disabilities, and handicaps.
Wood, P. (1980) · PubMed · Cited by 247
NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE DISABILITY STATUS SCALE
Kurtzke, J. F. (1970) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1970.tb05808.x · Cited by 156
A PROPOSAL FOR A UNIFORM MINIMAL RECORD OF DISABILITY IN MULTIPLE SCLEROSIS
Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05548.x · Cited by 127
STUDIES ON THE NATURAL HISTORY OF MULTIPLE SCLEROSIS 6. Clinical and Laboratory Findings at First Diagnosis
Kurtzke, J. F., Beebe, G. W., Nagler, B., Auth, T. L., Kurland, L. T., & Nefzger, M. D. (1972) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1972.tb07525.x · Cited by 68
THE SOCIO-ECONOMIC SCALE
Mellerup, E., Fog, T., Raun, N. E., Colville, P., de Rham, B., Hannah, B., & Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05549.x · Cited by 53
The effects of isoniazid on patients with multiple sclerosis; preliminary report.
Kurtzke, J. F., & Berlin, L. (1954) · PubMed · doi:10.1164/art.1954.70.4.577 · Cited by 23
ACUTE RESPIRATORY FAILURE IN MULTIPLE SCLEROSIS AND ITS MANAGEMENT
Guthrie, T. C., Kurtzke, J. F., & BERLIN, L. (1952) · Annals of Internal Medicine · doi:10.7326/0003-4819-37-6-1197 · Cited by 20

Show all 13 references

Sorted by citations

Items 101–200 of 1,135

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D. H., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 548
How patients with multiple sclerosis acquire disability
Lublin, F. D., Häring, D. A., Ganjgahi, H., Ocampo, A., Hatami, F., Čuklina, J., Aarden, P., Dahlke, F., Arnold, D. L., Wiendl, H., et al. (2022) · Brain · doi:10.1093/brain/awac016 · Cited by 549
Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis
Rothwell, P. M., McDowell, Z. C., Wong, C., & Dorman, P. J. (1997) · BMJ · doi:10.1136/bmj.314.7094.1580 · Cited by 551
Diffusion tensor magnetic resonance imaging in multiple sclerosis
Filippi, M., Cercignani, M., Inglese, M., Horsfield, M. A., & Comi, G. (2001) · Neurology · doi:10.1212/wnl.56.3.304 · Cited by 545
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
Brown, J. W. L., Coles, A. J., Horáková, D., Havrdová, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Trojano, M., Lugaresi, A., et al. (2019) · JAMA · doi:10.1001/jama.2018.20588 · Cited by 550
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
Durelli, L., Verdun, E., Barbero, P., Bergui, M., Versino, E., Ghezzi, A., Montanari, E., & Zaffaroni, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08430-1 · Cited by 545
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability
Martin, C. L., Phillips, B. A., Kilpatrick, T. J., Butzkueven, H., Tubridy, N. J., McDonald, E. A., & Galea, M. P. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070658 · Cited by 543
Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions
Davie, C. A., Hawkins, C. P., Barker, G. J., Brennan, A., Tofts, P. S., Miller, D. H., & McDonald, W. I. (1994) · Brain · doi:10.1093/brain/117.1.49 · Cited by 536
Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo
Absinta, M., Sati, P., Masuzzo, F., Nair, G., Sethi, V., Kolb, H., Ohayon, J., Wu, T., Cortese, I. C. M., & Reich, D. S. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2399 · Cited by 534
Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change
Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., & Weinstock-Guttman, B. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.12.009 · Cited by 528
Age at disability milestones in multiple sclerosis
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awh714 · Cited by 544
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A., Arnold, D. L., Markowitz, C., Shafer, S. J., Kasper, L. H., Waubant, E. L., Gazda, S. K., Fox, R. J., Panzara, M. A., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 525
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
Ascherio, A., Munger, K. L., White, R., Köchert, K., Simon, K. C., Polman, C. H., Freedman, M. S., Hartung, H., Miller, D. H., Montalbán, X., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5993 · Cited by 558
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Feys, P., Lamers, I., Francis, G., Benedict, R. H. B., Phillips, G. A., LaRocca, N. G., Hudson, L. D., & Rudick, R. A. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690824 · Cited by 518
Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis
Rao, S. M., Leo, G. J., Haughton, V. M., Aubin-Faubert, P. S., & Bernardin, L. (1989) · Neurology · doi:10.1212/wnl.39.2.161 · Cited by 516
The epidemiology of multiple sclerosis
Goodin, D. S. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 517
Impact of Walking Impairment in Multiple Sclerosis
LaRocca, N. G. (2011) · Patient · doi:10.2165/11591150-000000000-00000 · Cited by 508
Evidence of Axonal Damage in the Early Stages of Multiple Sclerosis and Its Relevance to Disability
Stefano, N. D., Narayanan, S., Francis, G., Arnaoutelis, R., Tartaglia, M. C., Antel, J. P., Matthews, P. M., & Arnold, D. L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.1.65 · Cited by 505
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients
Muraro, P. A., Douek, D. C., Packer, A., Chung, K., Guenaga, J., Cassiani‐Ingoni, R., Campbell, C., Memon, S. A., Nagle, J. W., Hakim, F. T., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041679 · Cited by 505
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations
Hobart, J. C., Cano, S. J., Zajicek, J. P., & Thompson, A. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70290-9 · Cited by 495
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H., Miller, D. H., Montalbán, X., Barkhof, F., Radue, E. W., Bauer, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61194-5 · Cited by 503
Gray matter atrophy is related to long‐term disability in multiple sclerosis
Fisniku, L. K., Chard, D., Jackson, J. S., Anderson, V. M., Altmann, D. R., Miszkiel, K., Thompson, A. J., & Miller, D. H. (2008) · Annals of Neurology · doi:10.1002/ana.21423 · Cited by 505
Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis
Kappos, L., Moeri, D., Radue, E. W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C. R., Weiner, H. L., Gasperini, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03053-0 · Cited by 499
Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis
Mostert, S., & Kesselring, J. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms779oa · Cited by 514
Defining high, medium, and low impact prognostic factors for developing multiple sclerosis
Tintore, M., Rovira, À., Río, J., Otero-Romero, S., Arrambide, G., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., Negrotto, L., et al. (2015) · Brain · doi:10.1093/brain/awv105 · Cited by 530
Thalamic atrophy and cognition in multiple sclerosis
Houtchens, M., Benedict, R., Killiany, R., Sharma, J., Jaisani, Z., Singh, B., Weinstock-Guttman, B., Guttmann, C., & Bakshi, R. (2007) · Neurology · doi:10.1212/01.wnl.0000276992.17011.b5 · Cited by 512
The role of interleukin-6 signaling in nervous tissue
Rothaug, M., Becker-Pauly, C., & Rose-John, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.018 · Cited by 491
Axonal damage correlates with disability in patients with relapsing- remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study
Stefano, N. D. (1998) · Brain · doi:10.1093/brain/121.8.1469 · Cited by 491
Automated segmentation of multiple sclerosis lesions by model outlier detection
Leemput, K. V., Maes, F., Vandermeulen, D., Colchester, A. C. F., & Suetens, P. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.938237 · Cited by 487
Quality of life in patients with multiple sclerosis
Janardhan, V., & Bakshi, R. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00312-x · Cited by 489
Vaccinations and the Risk of Relapse in Multiple Sclerosis
Confavreux, C., Suissa, S., Saddier, P., Bourdès, V., & Vukusic, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440501 · Cited by 490
Evidence of early cortical atrophy in MS
Stefano, N. D., Matthews, P. M., Filippi, M., Agosta, F., Luca, M. D., Bartolozzi, M. L., Guidi, L., Ghezzi, A., Montanari, E., Cifelli, A., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000055926.69643.03 · Cited by 482
Quality of life in multiple sclerosis: the impact of depression, fatigue and disability
Amato, M. P., Ponziani, G., Rossi, F., Liedl, C. L., Stefanile, C., & Rossi, L. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700511 · Cited by 506
Major differences in the dynamics of primary and secondary progressive multiple sclerosis
Thompson, A. J., Kermode, A. G., Wicks, D., MacManus, D. G., Kendall, B. E., Kingsley, D. P. E., & McDonald, W. I. (1991) · Annals of Neurology · doi:10.1002/ana.410290111 · Cited by 488
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
O’Riordan, J. I. (1998) · Brain · doi:10.1093/brain/121.3.495 · Cited by 480
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Mikol, D. D., Barkhof, F., Chang, P., Coyle, P. K., Jeffery, D., Schwid, S. R., Stubinski, B., & Uitdehaag, B. M. J. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70200-x · Cited by 484
Imaging axonal damage of normal-appearing white matter in multiple sclerosis
Fu, L. (1998) · Brain · doi:10.1093/brain/121.1.103 · Cited by 482
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Kappos, L., Gold, R., Miller, D. H., MacManus, D., Havrdová, E., Limmroth, V., Polman, C., Schmierer, K., Yousry, T., Yang, M.-H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61619-0 · Cited by 462
Fatigue in multiple sclerosis and its relationship to depression and neurologic disability
Bakshi, R., Shaikh, Z. A., Miletich, R. S., Czarnecki, D., Dmochowski, J., Henschel, K., Janardhan, V, Dubey, N., & Kinkel, P. R. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600308 · Cited by 480
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
Segal, B. M., Constantinescu, C. S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., & Kasper, L. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70173-x · Cited by 493
Progressive cerebral atrophy in multiple sclerosis A serial MRI study
Losseff, N. A., Wang, L., Lai, H. M., Yoo, D. S., Gawne-Cain, M. L., McDonald, W. I., Miller, D., & Thompson, A. J. (1996) · Brain · doi:10.1093/brain/119.6.2009 · Cited by 472
Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial
Cruz, F., Herschorn, S., Aliotta, P. J., Brin, M. F., Thompson, C., Lam, W., Daniell, G., Heesakkers, J. P. F. A., & Haag‐Molkenteller, C. (2011) · European Urology · doi:10.1016/j.eururo.2011.07.002 · Cited by 469
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Havrdová, E., Galetta, S. L., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., LUBLIN, F. D., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70021-3 · Cited by 468
Silent progression in disease activity–free relapsing multiple sclerosis
Cree, B., Hollenbach, J. A., Bove, R. M., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T. J., Zhu, A. H., Papinutto, N., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 468
Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
Dal-Bianco, A., Grabner, G., Kronnerwetter, C., Weber, M., Höftberger, R., Berger, T., Auff, E., Leutmezer, F., Trattnig, S., Lassmann, H., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1636-z · Cited by 463
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S. S., Hobart, J. C., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A. L., & Vollmer, T. L. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 480
Brain atrophy in clinically early relapsing–remitting multiple sclerosis
Chard, D. T., Griffin, C. M., Parker, G. J. M., Kapoor, R., Thompson, A. J., & Miller, D. H. (2002) · Brain · doi:10.1093/brain/awf025 · Cited by 366
Randomized controlled trial of interferon-beta-1a in secondary progressive MS
Li, D. K. B., Zhao, G., & Paty, D. W. (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Multiple sclerosis: a review
Farace, C., Melguizo, C., Asara, Y., Álvarez, P., Prados, J. C., Tolu, P., Delogu, G., Aránega, A., & Madeddu, R. (2011) · Cited by 458
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., & Lyons, J. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.029 · Cited by 465
Deep gray matter volume loss drives disability worsening in multiple sclerosis
Eshaghi, A., Prados, F., Brownlee, W. J., Altmann, D. R., Tur, C., Cardoso, M. J., Angelis, F. D., van de Pavert, S. H., Cawley, N., Stefano, N. D., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25145 · Cited by 454
Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis
Haas, J., Hug, A., Viehöver, A., Fritzsching, B., Falk, C. S., Filser, A., Vetter, T., Milkova, L., Korporal, M., Fritz, B., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200526065 · Cited by 450
The natural history of multiple sclerosis with childhood onset
Renoux, C., Vukusic, S., & Confavreux, C. (2008) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2008.04.009 · Cited by 450
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
LUBLIN, F. D., Miller, D. H., Freedman, M. S., Cree, B., Wolinsky, J. S., Weiner, H. L., Lubetzki, C., Hartung, H., Montalbán, X., Uitdehaag, B. M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01314-8 · Cited by 448
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
Kremenchutzky, M., Rice, G. P., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C. (2006) · Brain · doi:10.1093/brain/awh721 · Cited by 447
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
Miller, D. H., Albert, P. S., Barkhof, F., Francis, G., Frank, J. A., Hodgkinson, S., Lublin, F. D., Paty, D. W., Reingold, S. C., & Simon, J. (1996) · Annals of Neurology · doi:10.1002/ana.410390104 · Cited by 444
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
Chataway, J., Schuerer, N., Alsanousi, A., Chan, D., MacManus, D. G., Hunter, K., Anderson, V. M., Bangham, C. R. M., Clegg, S., Nielsen, C. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62242-4 · Cited by 456
Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality
Lobentanz, I. S., Asenbaum, S., Vass, K., Sauter, C., Klosch, G., Kollegger, H., Kristoferitsch, W., & Zeitlhofer, J. (2004) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2004.00257.x · Cited by 439
Efficacy and safety of modafinil (Provigil(R)) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
Rammohan, K. W. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.2.179 · Cited by 441
Long‐term evolution of multiple sclerosis disability in the treatment era
Cree, B., Gourraud, P., Oksenberg, J. R., Bevan, C. J., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A., Mowry, E. M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Validation of the Hospital anxiety and depression scale for use with multiple sclerosis patients
Honarmand, K., & Feinstein, A. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509347150 · Cited by 436
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial
Wolinsky, J. S., Narayana, P. A., O'Connor, P. W., Coyle, P. K., Ford, C. C., Johnson, K. P., Miller, A., Pardo, L., Kadosh, S. E., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 428
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004683 · Cited by 426
Prospective study on the relationship between infections and multiple sclerosis exacerbations
Buljevac, D., Flach, H. Z., Hop, W. C. J., Hijdra, D., Laman, J. D., Savelkoul, H. F. J., van der Meché, F. G. A., van Doorn, P. A., & Hintzen, R. Q. (2002) · Brain · doi:10.1093/brain/awf098 · Cited by 426
Anxiety disorders and their clinical correlates in multiple sclerosis patients
Korostil, M., & Feinstein, A. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506071161 · Cited by 424
Validation of the "World Health Organization Disability Assessment Schedule, WHODAS-2" in patients with chronic diseases
Garín, O., Ayuso‐Mateos, J. L., Almansa, J., Nieto‐Moreno, M., Chatterji, S., Vilagut, G., Alonso, J., Cieza, A., Svetskova, O., Burger, H., et al. (2010) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-8-51 · Cited by 434
Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis
Gordon‐Lipkin, E. M., Chodkowski, B., Reich, D. S., Smith, S. A., Pulicken, M., Balcer, L. J., Frohman, E. M., Cutter, G., & Calabresi, P. A. (2007) · Neurology · doi:10.1212/01.wnl.0000295995.46586.ae · Cited by 421
Effect of relapses on development of residual deficit in multiple sclerosis
LUBLIN, F. D., Baier, M. L., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 420
Early onset multiple sclerosis
Бойко, А. Н., Vorobeychik, G., Paty, D. W., Devonshire, V., & Sadovnick, A. D. (2002) · Neurology · doi:10.1212/wnl.59.7.1006 · Cited by 417
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Motl, R. W., Cohen, J. A., Benedict, R. H. B., Phillips, G. A., LaRocca, N. G., Hudson, L. D., & Rudick, R. A. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690823 · Cited by 410
Treatment of spasticity with botulinum toxin: A double‐blind study
Snow, B. J., Tsui, J. K. C., Bhatt, M. H., Varelas, M., Hashimoto, S. A., & Calne, D. B. (1990) · Annals of Neurology · doi:10.1002/ana.410280407 · Cited by 409
Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis
Mohr, D. C., Hart, S. L., Julian, L., Cox, D., & Pelletier, D. (2004) · BMJ · doi:10.1136/bmj.38041.724421.55 · Cited by 401
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
O'Connor, P. W., Filippi, M., Arnason, B. G. W., Comı, G., Cook, S. D., Goodin, D. S., Hartung, H.-P., Jeffery, D., Kappos, L., Boateng, F., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70226-1 · Cited by 404
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
Baranzini, S. E., Wang, J., Gibson, R. A., Galwey, N., Naegelin, Y., Barkhof, F., Radue, E.-W., Lindberg, R. L. P., Uitdehaag, B. M. G., Johnson, M. R., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddn388 · Cited by 476
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Cohen, J. A., Cutter, G., Fischer, J. S., Goodman, A. D., Heidenreich, F., Kooijmans, M., Sandrock, A., Rudick, R. A., Simon, J. H., Simonian, N. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.5.679 · Cited by 401
Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants
Rosa, V. D., Galgani, M., Porcellini, A., Colamatteo, A., Santopaolo, M., Zuchegna, C., Romano, A., Simone, S. D., Procaccini, C., Rocca, C. L., et al. (2015) · Nature Immunology · doi:10.1038/ni.3269 · Cited by 397
Focal thinning of the cerebral cortex in multiple sclerosis
Sailer, M. (2003) · Brain · doi:10.1093/brain/awg175 · Cited by 399
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyко, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70068-7 · Cited by 396
Diffusion tensor imaging of post mortem multiple sclerosis brain
Schmierer, K., Wheeler-Kingshott, C. A. M., Boulby, P. A., Scaravilli, F., Altmann, D. R., Barker, G. J., Tofts, P. S., & Miller, D. H. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.12.010 · Cited by 395
Menstrual cycle effects on cortical excitability
Smith, M., Keel, J. C., Greenberg, B. D., Adams, L. F., Schmidt, P. J., Rubinow, D., & Wassermann, E. M. (1999) · Neurology · doi:10.1212/wnl.53.9.2069 · Cited by 407
Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis
Filippi, M., Rocca, M. A., Martino, G., Horsfield, M. A., & Comi, G. (1998) · Annals of Neurology · doi:10.1002/ana.410430616 · Cited by 395
Principal components of functional connectivity: A new approach to study dynamic brain connectivity during rest
Leonardi, N., Richiardi, J., Gschwind, M., Simioni, S., Annoni, J., Schluep, M., Vuilleumier, P. O., & Ville, D. V. D. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.07.019 · Cited by 401
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
Pittock, S. J., Lennon, V. A., McKeon, A. B., Mandrekar, J. N., Weinshenker, B. G., Lucchinetti, C. F., O’Toole, O., & Wingerchuk, D. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70076-0 · Cited by 401
The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients
Armutlu, K., Cetisli-Korkmaz, N., Keser, İ., Sümbüloğlu, V., Akbıyık, D. İ., Güney, Z., & Karabudak, R. (2007) · International Journal of Rehabilitation Research · doi:10.1097/mrr.0b013e3280146ec4 · Cited by 396
A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis
Zivadinov, R. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.6.773 · Cited by 388
Neuropsychology of multiple sclerosis: A critical review
Rao, S. M. (1986) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688638608405173 · Cited by 386
Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel Index and the Functional Independence Measure
van der Putten, J. J. M. F., Hobart, J., Freeman, J. A., & Thompson, A. J. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.4.480 · Cited by 385
The Measurement of Fatigue in Patients With Multiple Sclerosis
Vercoulen, J. H. M. M. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550070080014 · Cited by 382
Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10
Rojas, O. L., Pröbstel, A.-K., Porfilio, E. A., Wang, A. A., Charabati, M., Sun, T., Lee, D. S. W., Galicia, G., Ramaglia, V., Ward, L. A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.035 · Cited by 382
Functional Magnetic Resonance Imaging Correlates of Fatigue in Multiple Sclerosis
Filippi, M., Rocca, M. A., Colombo, B., Falini, A., Codella, M., Scotti, G., & Comi, G. (2002) · NeuroImage · doi:10.1006/nimg.2001.1011 · Cited by 378
Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms
Nijeholt, G. J. L. À. (1998) · Brain · doi:10.1093/brain/121.4.687 · Cited by 376
Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
Fazekas, F., Deisenhammer, F., Strasser‐Fuchs, S., Nahler, G., & Mamoli, B. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09377-4 · Cited by 378
Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss.
Davie, C., Barker, G., Webb, S., Tofts, P., Thompson, A. J., Harding, A., Mcdonald, W., & Miller, D. (1995) · Brain : a journal of neurology · doi:10.1093/brain/118.6.1583 · Cited by 381
Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.
Dalton, C., Chard, D., Davies, G., Miszkiel, K., Altmann, D., Fernando, K., Plant, G., Thompson, A., & Miller, D. H. (2004) · Brain : a journal of neurology · doi:10.1093/brain/awh126 · Cited by 385
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
Tahara, M., Oeda, T., Okada, K., Kiriyama, T., Ochi, K., Maruyama, H., Fukaura, H., Nomura, K., Shimizu, Y., Mori, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30066-1 · Cited by 376
Effect of Exercise Training on Walking Mobility in Multiple Sclerosis: A Meta-Analysis
Snook, E. M., & Motl, R. W. (2008) · Neurorehabilitation and neural repair · doi:10.1177/1545968308320641 · Cited by 375
T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β
Durelli, L., Conti, L., Clerico, M., Boselli, D., Contessa, G., Ripellino, P., Ferrero, B., Eid, P., & Novelli, F. (2009) · Annals of Neurology · doi:10.1002/ana.21652 · Cited by 389
Eight-year follow-up study of brain atrophy in patients with MS
Fisher, E., Rudick, R. A., Simon, J. H., Cutter, G., Baier, M. L., Lee, J., Miller, D., Weinstock‐Guttman, B., Mass, M. K., Dougherty, D. S., et al. (2002) · Neurology · doi:10.1212/01.wnl.0000036271.49066.06 · Cited by 373

Authors: Kurtzke, J. F.
Affiliations: Georgetown University (US)
Corresponding author: Kurtzke, John F.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1983-11
Volume: 33
Issue: 11
Pages: 1444-1444
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.33.11.1444
OpenAlex: W2112165124
Cited by: 15,011
References: 13
Citations by year: 2026: 474 · 2025: 622 · 2024: 692 · 2023: 648 · 2022: 722 · 2021: 781 · 2020: 764 · 2019: 648 · 2018: 603 · 2017: 592 · 2016: 657 · 2015: 634 · 2014: 632 · 2013: 586 · 2012: 581
FWCI: 9.57
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Health Sciences › Health Professions › Speech and Hearing › Voice and Speech Disorders
Keywords: multiple sclerosis, Expanded Disability Status Scale, disability assessment, neurological deficit, functional systems, pyramidal system, cerebellar function, brainstem, sensory impairment, bowel and bladder dysfunction, visual impairment
MeSH terms: Humans, Multiple Sclerosis, Nervous System Diseases, Neurologic Examination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks